Table 3.

Chemokine production due to the interaction between HIV-1-specific antibody, target cells expressing HIV envelope glycoproteins, and NK effector cells

Antibody-effector cell combinationsaβ-Chemokine (pg/ml)b
MIP-1αMIP-1βRANTES
Patient IgG + NK cells4,454 ± 1,935992 ± 6378,260 ± 1,725
HIV-negative IgG + NK cells1,507 ± 7521,032 ± 4896,021 ± 2,006
Patient Fab + NK cells1,740 ± 940964 ± 6806,084 ± 1,916
Patient IgG (no NK cells)<10 ± 070 ± 56<10 ± 0
  • a Antibody-effector cell combinations were added to CEM213 target cells for 18 h, and the supernatant fluid was assayed for β-chemokine levels by ELISA.

  • b Mean ± standard error of three separate experiments, except in the case of the Fab-NK combination, where values represent the mean ± standard error of two separate experiments. Significant differences ( P < 0.05 ) were noted by paired t test for RANTES production by patient IgG + NK cells versus HIV-negative IgG + NK cells or patient IgG (no NK cells).